Upadacitinib (Rinvoq®) is indicated for active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||01/09/2021|
|Rapid review completed||11/10/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that upadacitinib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.